Skip to main content

Keyboard Shortcuts

Key Pair Function
Alt S Search Box
Alt T Top of Page
Alt H Home Page
Alt Index Button
Alt Next Button
Alt Prev Button
TLDEF Logo

TLDEF's Trans Health Project

Working for Transgender Equal Rights
Menu
  • Trans Health Insurance Tutorial
    • Choosing a Plan
    • Understanding Your Plan
    • Applying for Coverage
    • Understanding a Denial
    • Appealing a Denial
  • Resources
    • Health Insurance Medical Policies
    • Medical Organization Statements
    • State Health Insurance Laws and Guidance
    • Medicaid Regulations and Guidance
    • Gender Centers
    • Trans Health Care Providers
    • State Employee Health Plans
    • Financial Aid for Transgender Surgeries
  • Tools
    • Legal Analysis
    • Medical Necessity Literature Reviews
    • Reporting Medical Provider Discrimination
    • Training Materials for Advocates
    • Provider Medical Necessity Letter Checklists
  • About Us
    • About TLDEF's Trans Health Project
    • Privacy Policy
  • Contact Us
    • Contact TLDEF's Trans Health Project
    • Contact TLDEF
Previous Page
Prev
Home
Home
Up
Up
Next Page
Next
  •  Home
  • Resources
  • Health Insurance Medical Policies
  • Current: AmeriHealth - Gonadotropin-Releasing Hormone Agonist (Eligard®, Lupron Depot®)

Prev Index Youth Services [9 of 81] Next

AmeriHealth

Gonadotropin-Releasing Hormone Agonist (Eligard®, Lupron Depot®)


Policy: Gonadotropin-Releasing Hormone Agonist (Eligard®, Lupron Depot®)
Policy Number: 08.01.33b
Last Update: 2019-12-02
Issued in: New Jersey, Pennsylvania

Youth Services:

Leuprolide acetate for injection is considered medically necessary and, therefore, covered for puberty suppression when all of the following criteria are met:

  • The adolescent has demonstrated a long-lasting and intense pattern of gender nonconformity or gender dysphoria (whether suppressed or expressed), in accordance with criteria established in the Diagnostic and Statistical Manual of Mental Disorders - Fifth Edition, [DSM-5].
  • Gender dysphoria emerged or worsened with the onset of puberty.
  • The individual has reached at least Tanner stage 2 of development.

Back to top

Updated on Jun 10, 2020

Donate Now Donate Now

Join Our Mailing List

Facebook Button Twitter Button Instagram Button
 Keyboard Shortcuts
 Privacy Policy
 TLDEF Website

Copyright © 2023 Transgender Legal Defense & Education Fund, Inc.  |  520 8th Avenue, Suite 2204, New York, NY 10018   Tel: 646.862.9396   Fax: 646.993.1684